Multispecific antibodies facilitating selective light chain pairing

Patent metadata

Field	Value
Publication number	US-11820809-B2
Application number	US-201715687055-A
Country	US
Kind code	B2
Filing date	Aug 25, 2017
Priority date	Aug 26, 2016
Publication date	Nov 21, 2023
Grant date	Nov 21, 2023

Abstract

Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.

First claim

The invention claimed is:

1. An antibody or antigen-binding fragment thereof, comprising:
(a) a heavy chain A and a light chain A, wherein the heavy chain comprises a variable domain V H A linked to a dimerization domain CH2 H and the light chain comprises a variable domain V L A linked to a dimerization domain CH2 L , wherein both CH2 H and CH2 L are an IgM constant domain MC H 2 having the amino acid sequence of SEQ ID NO: 1, wherein CH2 H and CH2 L form a dimer, and wherein V H A and V L A form a first paratope AA, and
(b) a heavy chain B and a light chain B, wherein the heavy chain B comprises a variable domain V H B and the light chain B comprises a variable domain V L B, wherein V H B is linked to a dimerization domain C H1 and V L B is linked to a dimerization domain C L , wherein C H1 and C L form a C H1 /C L dimer, wherein C H1 has the amino acid sequence of a C H1 domain comprised in SEQ ID NO: 9 and CL has the amino acid sequence of a CL domain comprised in SEQ ID NO: 8 and wherein V H B and V L B form a second paratope BB; and
wherein CH2 H is linked via a hinge region to a constant domain C H 2A, and C H1 is linked via a hinge region to a constant domain C H 2B, and wherein C H 2A is linked to a constant domain C H 3A and C H 2B is linked to a constant domain C H 3B; and
wherein:
(i) heavy chain A comprises one or more hole amino acid substitution(s) of knob-into-hole amino acid substitutions, wherein heavy chain A has reduced Protein A affinity as determined by Protein A chromatography and heavy chain B comprises one or more knob amino acid substitution(s) of knob-into-hole amino acid substitutions, or
(ii) heavy chain B comprises one or more hole amino acid substitution(s) of knob-into-hole amino acid substitutions, wherein heavy chain B has reduced Protein A affinity as determined by Protein A chromatography and heavy chain A comprises one or more knob amino acid substitution(s) of knob-into-hole amino acid substitutions; and

wherein heavy chain A dimerizes with heavy chain B; and
wherein the antibody or antigen-binding fragment thereof is selectable by a method comprising a step of selecting for Protein A binding, and not comprising a step of selecting for the presence of a C H1 domain or a C L domain.

2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is multispecific.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein paratopes AA and BB are not identical to each other.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein:
(a) heavy chain A comprises a further heavy chain variable domain V H X linked to V H A and light chain A comprises a further light chain variable domain V L X linked to V L A, wherein V H X and V L X form a third paratope XX; and/or
(b) heavy chain B comprises a further heavy chain variable domain V H Y linked to V H B and light chain B comprises a further light chain variable domain V L Y linked to V L B, wherein V H Y and V L Y form a fourth paratope YY.

5. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises one or more of:
(a) a T366Y mutation and optionally further an S354C and T166W mutation in one heavy chain, and a Y407T mutation and optionally further a Y349C, T366S, L368A, and Y407V mutation in the other heavy chain;
(b) a T366W mutation in one heavy chain, and a T366S, L368A and Y407V mutation in the other heavy chain;
(c) a F405L mutation in one heavy chain, and a K409R mutation in the other heavy chain;
(d) a T350V, L351Y, F405A, and Y407V mutation in one heavy chain, and a T350V, T366L, K392L, and T394W mutation in the other heavy chain;
(e) a K409D and K392D mutation in one heavy chain, and a D399K and E356K mutation in the other heavy chain;
(f) a D221E, P228E, and L368E mutation in one heavy chain, and a D221R, P228R, and K409R mutation in the other heavy chain;
(g) a S364H and F405A mutation in one heavy chain, and a Y349T and T394F mutation in the other heavy chain;
(h) an Fc region or part thereof of one heavy chain from IgG3, and an Fc region or part thereof of the other heavy chain from IgG1, IgG2, or IgG4;
(i) a H435R and Y436F mutation in one heavy chain, and a T407T mutation in the other heavy chain; and/or
(j) a H435R mutation in one heavy chain, and no mutation in the other heavy chain.

6. The antibody or antigen-binding fragment thereof of claim 1 , wherein
(i) heavy chain A comprises one or more hole amino acid substitution(s) of knob-into-hole amino acid substitutions, and an IgG3 C H 3 domain or a H435R mutation, and heavy chain B comprises one or more knob amino acid substitution(s) of knob-into-hole amino acid substitutions and comprises an IgG1, 2 or 4 C H 3 domain if heavy chain A comprises the IgG3 C H 3 domain, or
(ii) heavy chain B comprises one or more hole amino acid substitution(s) of knob-into-hole amino acid substitutions, and an IgG3 C H 3 domain or a H435R mutation, and heavy chain A comprises one or more knob amino acid substitution(s) of knob-into-hole amino acid substitutions and comprises an IgG1, 2 or 4 C H 3 domain if heavy chain B comprises the IgG3 C H 3 domain.

7. One or more polynucleotides encoding for an antibody or antigen-binding fragment thereof according to claim 2 .

8. One or more expression vectors comprising the one or more polynucleotides of claim 7 .

9. A cell comprising the one or more polynucleotides of claim 7 .

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the antibody or antigen-binding fragment thereof according to claim 1 .

11. A cell comprising the one or more expression vectors of claim 8 .

12. A method of isolating the antibody or antigen-binding fragment thereof of claim 1 ,
from a solution comprising the heavy chain A and the light chain A, and the heavy chain B and the light chain B according to claim 2
by purifying the antibody or antigen-binding fragment thereof.

13. The method of claim 12 , wherein the antibody or antigen-binding fragment thereof is purified by
(a) selecting for Protein A binding.

14. The method of claim 12 ,
the antibody or antigen-binding fragment thereof is purified by selecting for Protein A binding, characterized in that the method does not comprise selecting for the presence of a C H1 domain or a C L domain, or for the absence of a C H2 domain.

Assignees

• Sanofi Sa

Inventors

• Rao Ercole
• Beil Christian
• Lange Christian
• Kroll Katja
• Leuschner Wulf-Dirk
• Focken Ingo
• Langer Thomas
• Spindler Nadja

Classifications

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title

• C07K16/244 Primary

  Interleukins [IL] · CPC title

• C07K16/247

  IL-4 · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title